Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$16.68M$16.68Mderived+254.4% vs Q4 2018 Net Income-$771.00K-$771.00KderivedN/M vs Q4 2018 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$1,330,000N/M Operating Cash Flowderived-$13,974,000N/M Free Cash Flowderived-$15,150,000N/M Margins · derivedOperating margin-8.0%+260.7 pt vs Q4 2018
Net margin-4.6%+243.6 pt vs Q4 2018
ended Dec 31, 2019 · filed Mar 13, 2020 · 73 d after period end